- Home
- WKC vs GPCR Comparison
WKC vs GPCR Comparison
Compare WKC & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKC
- GPCR
- Stock Information
- Founded
- WKC 1984
- GPCR 2016
- Country
- WKC United States
- GPCR United States
- Employees
- WKC N/A
- GPCR N/A
- Industry
- WKC Oil Refining/Marketing
- GPCR
- Sector
- WKC Energy
- GPCR
- Exchange
- WKC Nasdaq
- GPCR Nasdaq
- Market Cap
- WKC 1.7B
- GPCR 1.6B
- IPO Year
- WKC N/A
- GPCR 2023
- Fundamental
- Price
- WKC $28.07
- GPCR $27.06
- Analyst Decision
- WKC Hold
- GPCR Strong Buy
- Analyst Count
- WKC 5
- GPCR 7
- Target Price
- WKC $30.20
- GPCR $81.29
- AVG Volume (30 Days)
- WKC 947.6K
- GPCR 1.0M
- Earning Date
- WKC 02-20-2025
- GPCR 03-07-2025
- Dividend Yield
- WKC 2.42%
- GPCR N/A
- EPS Growth
- WKC 28.11
- GPCR N/A
- EPS
- WKC 2.24
- GPCR N/A
- Revenue
- WKC $44,410,500,000.00
- GPCR N/A
- Revenue This Year
- WKC N/A
- GPCR N/A
- Revenue Next Year
- WKC $4.58
- GPCR N/A
- P/E Ratio
- WKC $12.53
- GPCR N/A
- Revenue Growth
- WKC N/A
- GPCR N/A
- 52 Week Low
- WKC $21.38
- GPCR $23.50
- 52 Week High
- WKC $31.71
- GPCR $62.74
- Technical
- Relative Strength Index (RSI)
- WKC 53.64
- GPCR 42.52
- Support Level
- WKC $27.62
- GPCR $23.50
- Resistance Level
- WKC $28.40
- GPCR $27.68
- Average True Range (ATR)
- WKC 0.58
- GPCR 1.71
- MACD
- WKC 0.11
- GPCR 0.20
- Stochastic Oscillator
- WKC 79.63
- GPCR 51.30
About WKC World Kinect Corporation
World Kinect Corp is a energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers . It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. Company operate in three reportable segments consisting of aviation, land, and marine. Company earn majority of revenue from Aviation segment.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.